Evidence map›Paper›PMID 36071577›Full record

ArticleAmerican journal of hematology2022

Erythroferrone contributes to iron mobilization for embryo erythropoiesis in iron-deficient mouse pregnancies.

Veena Sangkhae, Vivian Yu, Richard Coffey, Kimberly O O'Brien, Tomas Ganz, Elizabeta Nemeth

Open access · greenAbstract read
In one paragraph

Article in American journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Iron and Pregnancy.Advances in experimental medicine and biology · 2025
    Review
  5. Anemia in Pregnancy With CKD.Kidney international reports · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Veena SangkhaeCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0001-7397-0815
Vivian YuCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Richard CoffeyCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Kimberly O O'BrienDivision of Nutritional Sciences, Cornell University, Ithaca, New York, USA.
Tomas GanzCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-2830-5469
Elizabeta NemethCenter for Iron Disorders, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-3477-2397
University of California, Los Angeles · USCornell University · US

Funding

MECHANISM OF ACTION OF ERYTHROFERRONE AND PATHOLOGICAL IMPLICATIONSR01DK126680 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GANZ, TOMAS · 2020 to 2024
$2.6M
Iron physiology and pathology in pregnancyR01HD096863 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEMETH, ELIZABETA · 2019 to 2023
$2.1M
Iron and Pregnancy: Regulatory Mechanisms and Adverse OutcomesK01DK127004 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SANGKHAE, VEENA · 2021 to 2025
$761k
Erythroferrone and Its Impact on Maternal and Neonatal Iron HomeostasisR21HD098864 · NICHD · CORNELL UNIVERSITY · PI NEMETH, ELIZABETA, O'BRIEN, KIMBERLY O · 2019 to 2020
$445k
NICHD NIH HHS R01 HD096863NICHD NIH HHS R21 HD098864NIDDK NIH HHS K01 DK127004NIDDK NIH HHS R01 DK126680
6 · The paper itself

Abstract

Erythroferrone (ERFE) is an erythroblast-secreted regulator of iron metabolism. The production of ERFE increases during stress erythropoiesis, leading to decreased hepcidin expression and mobilization of iron. Pregnancy requires a substantial increase in iron availability to sustain maternal erythropoietic expansion and fetal development and is commonly affected by iron deficiency. To define the role of ERFE during iron-replete or iron-deficient pregnancy, we utilized mouse models expressing a range of ERFE levels: transgenic (TG) mice overexpressing ERFE, wild-type (WT), and ERFE knockout (KO) mice. We altered maternal iron status using diets with low or standard iron content and performed the analysis at E18.5. Iron deficiency increased maternal ERFE in WT pregnancy. Comparing different maternal genotypes, ERFE TG dams had lower hepcidin relative to their liver iron load but similar hematological parameters to WT dams on either diet. In ERFE KO dams, most hematologic and iron parameters were comparable to WT, but mean corpuscular volume (MCV) was decreased under both iron conditions. Similar to dams, TG embryos had lower hepcidin on both diets, but their hematologic parameters did not differ from those of WT embryos. ERFE KO embryos had lower MCV than WT embryos on both diets. The effect was exacerbated under iron-deficient conditions where ERFE KO embryos had higher hepcidin, lower Hb and Hct, and lower brain iron concentration compared to WT embryos, indicative of iron restriction. Thus, under iron-deficient conditions, maternal and embryo ERFE facilitate iron mobilization for embryonic erythropoiesis.

Indexed as

HepcidinsIron DeficienciesAnimalsErythropoiesisFemaleIronMiceMice, KnockoutPregnancyHepcidinsIron

Identifiers

PMID36071577
PMCPMC9462668
OpenAlexW4290422823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.